Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon α
K Merx, MC Müller, S Kreil, T Lahaye, P Paschka… - Leukemia, 2002 - nature.com
The degree of tumor load reduction as measured by cytogenetic response is an important
prognostic factor for chronic myelogenous leukemia (CML) patients on therapy. We sought …
prognostic factor for chronic myelogenous leukemia (CML) patients on therapy. We sought …
Molecular monitoring of response to imatinib (Glivec®) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous …
P Paschka, MC Müller, K Merx, S Kreil, C Schoch… - Leukemia, 2003 - nature.com
A significant proportion of chronic myeloid leukemia (CML) patients achieve a major
cytogenetic remission (MCR) to imatinib therapy after failing interferon (IFN) α-based …
cytogenetic remission (MCR) to imatinib therapy after failing interferon (IFN) α-based …
Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon α/ara-C
MC Müller, N Gattermann, T Lahaye, MWN Deininger… - Leukemia, 2003 - nature.com
We sought to determine dynamics of BCR-ABL mRNA expression levels in 139 patients with
chronic myelogenous leukemia (CML) in early chronic phase, randomized to receive …
chronic myelogenous leukemia (CML) in early chronic phase, randomized to receive …
BCR-ABL mRNA levels at and after the time of a complete cytogenetic response (CCR) predict the duration of CCR in imatinib mesylate–treated patients with CML
RD Press, Z Love, AA Tronnes, R Yang, T Tran… - Blood, 2006 - ashpublications.org
Although most patients with chronic myeloid leukemia (CML) treated with imatinib mesylate
achieve a complete cytogenetic response (CCR), some patients will relapse. To determine …
achieve a complete cytogenetic response (CCR), some patients will relapse. To determine …
A half-log increase in BCR-ABL RNA predicts a higher risk of relapse in patients with chronic myeloid leukemia with an imatinib-induced complete cytogenetic …
RD Press, C Galderisi, R Yang, C Rempfer… - Clinical Cancer …, 2007 - AACR
Purpose: Imatinib induces a complete cytogenetic response (CCR) in most chronic myeloid
leukemia patients in chronic phase. Although CCR is usually durable, a minority of patients …
leukemia patients in chronic phase. Although CCR is usually durable, a minority of patients …
Different kinetic patterns of BCR‐ABL transcript levels in imatinib‐treated chronic myeloid leukemia patients after achieving complete cytogenetic response
YZ Qin, YR Liu, HH Zhu, JL Li, GR Ruan… - International Journal …, 2008 - Wiley Online Library
Bone marrow BCR‐ABL transcript levels were monitored serially by real‐time quantitative
PCR in 46 imatinib‐treated chronic myeloid leukemia patients after achieving complete …
PCR in 46 imatinib‐treated chronic myeloid leukemia patients after achieving complete …
Monitoring patients in complete cytogenetic remission after treatment of CML in chronic phase with imatinib: patterns of residual leukaemia and prognostic factors for …
D Marin, J Kaeda, R Szydlo, S Saunders, A Fleming… - Leukemia, 2005 - nature.com
We monitored BCR–ABL transcript levels by quantitative real-time PCR in 103 patients
treated with imatinib for chronic myeloid leukaemia in chronic phase for a median of 30.3 …
treated with imatinib for chronic myeloid leukaemia in chronic phase for a median of 30.3 …
Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid …
Purpose: Most patients with chronic-phase chronic myeloid leukemia (CML) who receive
imatinib achieve a complete cytogenetic remission (CCgR) and low levels of BCR-ABL …
imatinib achieve a complete cytogenetic remission (CCgR) and low levels of BCR-ABL …
Serial monitoring of BCR–ABL by peripheral blood real‐time polymerase chain reaction predicts the marrow cytogenetic response to imatinib mesylate in chronic …
L Wang, K Pearson, L Pillitteri… - British journal of …, 2002 - Wiley Online Library
Imatinib mesylate (trade name Glivec® or Gleevec) is emerging as an important therapy in
the management of chronic myeloid leukaemia (CML). It is clinically useful to monitor the …
the management of chronic myeloid leukaemia (CML). It is clinically useful to monitor the …
Molecular response to imatinib in late chronic-phase chronic myeloid leukemia
G Rosti, G Martinelli, S Bassi, M Amabile, E Trabacchi… - Blood, 2004 - ashpublications.org
Imatinib is a tyrosine-kinase inhibitor that binds to ABL proteins and induces cytogenetic
remissions in patients with chronic myeloid leukemia (CML). In these patients measuring …
remissions in patients with chronic myeloid leukemia (CML). In these patients measuring …
相关搜索
- early reduction cytogenetic response
- transcript levels cytogenetic response
- early reduction transcript levels
- cml patients cytogenetic response
- early reduction cml patients
- cml patients transcript levels
- transcript levels bcr abl
- failure of interferon cytogenetic response
- patients with cml bcr abl
- early reduction failure of interferon
- abl mrna cytogenetic response
- early reduction abl mrna
- transcript levels failure of interferon
- cml patients failure of interferon
- failure of interferon abl mrna
- patients with cml imatinib mesylate